MedPath

Janssen-Cilag B.V.

🇳🇱Netherlands
Ownership
-
Employees
-
Market Cap
-
Website

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2008-06-16
Last Posted Date
2014-04-28
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
27
Registration Number
NCT00697658

The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

Phase 3
Completed
Conditions
Anemia
First Posted Date
2007-03-13
Last Posted Date
2011-02-01
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
176
Registration Number
NCT00446576

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

Completed
Conditions
Multiple Myeloma
Hematological Neoplasms
Interventions
First Posted Date
2007-02-27
Last Posted Date
2014-01-14
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
331
Registration Number
NCT00440765

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

Completed
Conditions
Hematological Neoplasms
Multiple Myeloma
Interventions
First Posted Date
2007-02-27
Last Posted Date
2015-04-16
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
11
Registration Number
NCT00440479

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Completed
Conditions
Anemia
Neoplasms
Interventions
First Posted Date
2006-11-14
Last Posted Date
2012-11-06
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
1927
Registration Number
NCT00398749

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Phase 4
Completed
Conditions
Anemia
Neoplasm
First Posted Date
2006-01-30
Last Posted Date
2011-01-14
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
316
Registration Number
NCT00283465

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Completed
Conditions
Anemia
Neoplasms
Interventions
First Posted Date
2005-12-12
Last Posted Date
2014-05-07
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
492
Registration Number
NCT00264108

An Observational Study of Blood Management Techniques in Oncology Surgical Treatment

Completed
Conditions
Anemia
Blood Loss, Surgical
Neoplasms
Interventions
Procedure: Oncological surgery
First Posted Date
2005-12-12
Last Posted Date
2014-04-28
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
488
Registration Number
NCT00264095

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Phase 4
Completed
Conditions
Anemia
Neoplasms
First Posted Date
2005-09-22
Last Posted Date
2011-05-19
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
110
Registration Number
NCT00216541
© Copyright 2025. All Rights Reserved by MedPath